Alpha-9 Oncology
Vancouver, CA · 10 known investors
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development. The company serves patients with cancer through novel drug candidates advancing in clinical trials.
Founders & leadership
FB
François BénardMD
KL
Kuo-Shyan LinPhD
DP
David PerrinPhD
Investors · 10
Andreessen HorowitzMenlo Park · $500K – $50M
Delos CapitalCambridge
General CatalystSan Francisco · $30M
Lightspeed Venture PartnersMenlo Park · $1.7M – $87M
Longitude CapitalMenlo Park · $10M – $30M
Lumira VenturesToronto · $1M – $10M
Nextech InvestZurich · $648K – $3.2M
RA CapitalBoston
Samsara BioCapitalPalo Alto
Digitalis VenturesreportedNew York · $100K – $10M
In the news
- Alpha-9 becomes latest radiopharma to secure funds with $175m Series C - Pharmaceutical Technologypharmaceutical-technology.com · 2024
- Lumira Ventures Invests in Alpha-9 Oncology’s $175 Million Oversubscribed Series C to Support Development of Their Robust Clinical Pipeline of Radiopharmaceuticals - Lumira Ventures | Venture Capital Life Sciences | Canadalumiraventures.com · 2024
- Radiopharma Alpha-9 raises $175M series C to fund clinical pushfiercebiotech.com · 2024
- Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticals - Alpha-9 Oncologya9oncology.com · 2024
- Alpha-9 Oncology Inc. Announces $175 Million Oversubscribed Series C Financing to Advance Robust Clinical Pipeline of Radiopharmaceuticalsprnewswire.com · 2024